Piroxicam cinnamate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Piroxicam cinnamate is an anti-inflammatory drug indicated to treat pain and inflammation.

Generic Name
Piroxicam cinnamate
DrugBank Accession Number
DB15883
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 461.49
Monoisotopic: 461.104541898
Chemical Formula
C24H19N3O5S
Synonyms
  • Cinnoxicam
  • Piroxicam cinnamate
  • Piroxicam cinnamic acid ester
External IDs
  • SPA-S-510
  • SPA-S-51O

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofAnkylosing spondylitis (as)•••••••••••••••••• •••••••••••• ••••••
Symptomatic treatment ofOsteoarthritis (oa)•••••••••••••••••• •••••••••••• ••••••
Symptomatic treatment ofRheumatoid arthritis•••••••••••••••••• •••••••••••• ••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7E8Q32N75N
CAS number
87234-24-0
InChI Key
GPUVGQIASQNZET-CCEZHUSRSA-N
InChI
InChI=1S/C24H19N3O5S/c1-27-22(24(29)26-20-13-7-8-16-25-20)23(18-11-5-6-12-19(18)33(27,30)31)32-21(28)15-14-17-9-3-2-4-10-17/h2-16H,1H3,(H,25,26,29)/b15-14+
IUPAC Name
2-methyl-1,1-dioxo-3-[(pyridin-2-yl)carbamoyl]-2H-1lambda6,2-benzothiazin-4-yl (2E)-3-phenylprop-2-enoate
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(OC(=O)\C=C\C2=CC=CC=C2)C2=C(C=CC=C2)S1(=O)=O

References

General References
  1. AIFA Product Information: SINARTROL (piroxicam cinnamate) tablet, suppository, and cream [Link]
ChemSpider
4940766
RxNav
33787
ChEBI
135749
ChEMBL
CHEMBL2106889
ZINC
ZINC000000608032

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CreamTopical1.5 %
SuppositoryRectal30 MG
TabletOral15 MG
TabletOral30 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0022 mg/mLALOGPS
logP4.61ALOGPS
logP3.49Chemaxon
logS-5.3ALOGPS
pKa (Strongest Acidic)11.6Chemaxon
pKa (Strongest Basic)3.96Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area105.67 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity126.61 m3·mol-1Chemaxon
Polarizability46.25 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0003900000-b254e9e6e5dfb269eddc
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-1504900000-9a8b6a960251989f41bf
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03ka-3504900000-ac7118c54fa81b6c3d1b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-3923600000-3c463d8b9b6cfa21e641
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0092100000-122dc63f2c65992b9339
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-4965400000-a786380d06939b504176
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-214.1311191
predicted
DarkChem Lite v0.1.0
[M+H]+214.6625191
predicted
DarkChem Lite v0.1.0
[M+Na]+213.9341191
predicted
DarkChem Lite v0.1.0

Drug created at September 24, 2020 20:35 / Updated at May 07, 2021 21:08